leflunomide has been shown to be as effective as methotrexate, albeit with a higher rate of particular adverse events including gastrointestinal disturbances, hypertension, skin rashes and alopecia.

Researchers in the Netherlands therefore evaluated another DMARD, leflunomide, effective in psoriatic arthritis and rheumatoid arthritris, in a double-blind, randomized, placebo-controlled trial ...